American Journal of Clinical Dermatology, ISSN 1175-0561, 2010, Volume 11, Issue 3, pp. 157 - 170
Pityriasis rubra pilaris (PRP) is a rare inflammatory dermatosis of unknown etiology, and finding a successful therapy can be challenging. PRP occurs equally...
Antiretrovirals | Acitretin | Corticosteroids | Calcipotriol | Ciclosporin | Children | Efalizumab | Adalimumab | Azathioprine | Therapeutic use | EXTRACORPOREAL PHOTOCHEMOTHERAPY | INITIAL PRESENTATION | CUTANEOUS MANIFESTATION | DERMATOMYOSITIS | THERAPY | TOPICAL TREATMENT | ACITRETIN | PATIENT | INFLIXIMAB | EXACERBATION | DERMATOLOGY | Pityriasis Rubra Pilaris - classification | Diagnosis, Differential | Biopsy | Humans | Dermatologic Agents - therapeutic use | Pityriasis Rubra Pilaris - diagnosis | Pityriasis Rubra Pilaris - therapy | Pityriasis Rubra Pilaris - etiology | Administration, Topical | Skin - pathology
Antiretrovirals | Acitretin | Corticosteroids | Calcipotriol | Ciclosporin | Children | Efalizumab | Adalimumab | Azathioprine | Therapeutic use | EXTRACORPOREAL PHOTOCHEMOTHERAPY | INITIAL PRESENTATION | CUTANEOUS MANIFESTATION | DERMATOMYOSITIS | THERAPY | TOPICAL TREATMENT | ACITRETIN | PATIENT | INFLIXIMAB | EXACERBATION | DERMATOLOGY | Pityriasis Rubra Pilaris - classification | Diagnosis, Differential | Biopsy | Humans | Dermatologic Agents - therapeutic use | Pityriasis Rubra Pilaris - diagnosis | Pityriasis Rubra Pilaris - therapy | Pityriasis Rubra Pilaris - etiology | Administration, Topical | Skin - pathology
Journal Article
JAMA, ISSN 0098-7484, 01/2011, Volume 305, Issue 4, pp. 391 - 399
Sarcoidosis is a multisystem granulomatous disorder that most often affects the lungs and may cause significant morbidity. Sarcoidosis can manifest as...
MEDICINE, GENERAL & INTERNAL | POSITRON-EMISSION-TOMOGRAPHY | LUNG LYMPHOCYTES-T | NEUROSARCOIDOSIS | SUSCEPTIBILITY | METHOTREXATE | ALVEOLAR MACROPHAGES | PROGRESSIVE PULMONARY SARCOIDOSIS | AFRICAN-AMERICANS | HYPERTENSION | PENTOXIFYLLINE | Sarcoidosis - diagnosis | Diagnosis, Differential | Humans | Middle Aged | Sarcoidosis - immunology | Sarcoidosis - drug therapy | Sarcoidosis - genetics | Female | Delayed Diagnosis | Adrenal Cortex Hormones - therapeutic use | Molecular Targeted Therapy | Sarcoidosis - pathology | Therapy | Sarcoidosis | Medical diagnosis | Pathogenesis | Medical treatment
MEDICINE, GENERAL & INTERNAL | POSITRON-EMISSION-TOMOGRAPHY | LUNG LYMPHOCYTES-T | NEUROSARCOIDOSIS | SUSCEPTIBILITY | METHOTREXATE | ALVEOLAR MACROPHAGES | PROGRESSIVE PULMONARY SARCOIDOSIS | AFRICAN-AMERICANS | HYPERTENSION | PENTOXIFYLLINE | Sarcoidosis - diagnosis | Diagnosis, Differential | Humans | Middle Aged | Sarcoidosis - immunology | Sarcoidosis - drug therapy | Sarcoidosis - genetics | Female | Delayed Diagnosis | Adrenal Cortex Hormones - therapeutic use | Molecular Targeted Therapy | Sarcoidosis - pathology | Therapy | Sarcoidosis | Medical diagnosis | Pathogenesis | Medical treatment
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 02/2013, Volume 85, Issue 3, pp. 289 - 305
The worldwide incidence of Alzheimer's disease (AD) is increasing with estimates that 115 million individuals will have AD by 2050, creating an unsustainable...
Tau | Amyloid | GWAS | Clinical trial failures | Alzheimer's | DIFFERENTIAL-DIAGNOSIS | INSULIN-DEGRADING ENZYME | BIOMARKER SIGNATURE | CHOLINESTERASE-INHIBITORS | MILD COGNITIVE IMPAIRMENT | NATIONAL INSTITUTE | A-BETA | PHARMACOLOGY & PHARMACY | CEREBROSPINAL-FLUID TAU | PRECURSOR PROTEIN | GAMMA-SECRETASE | Gene Expression Regulation - drug effects | Animals | Amyloid - metabolism | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Humans | Alzheimer Disease - metabolism | Amyloid beta-Peptides - metabolism | Alzheimer Disease - drug therapy | Biomarkers | tau Proteins - metabolism | Amyloid Precursor Protein Secretases - antagonists & inhibitors | Alzheimer Disease - genetics
Tau | Amyloid | GWAS | Clinical trial failures | Alzheimer's | DIFFERENTIAL-DIAGNOSIS | INSULIN-DEGRADING ENZYME | BIOMARKER SIGNATURE | CHOLINESTERASE-INHIBITORS | MILD COGNITIVE IMPAIRMENT | NATIONAL INSTITUTE | A-BETA | PHARMACOLOGY & PHARMACY | CEREBROSPINAL-FLUID TAU | PRECURSOR PROTEIN | GAMMA-SECRETASE | Gene Expression Regulation - drug effects | Animals | Amyloid - metabolism | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Humans | Alzheimer Disease - metabolism | Amyloid beta-Peptides - metabolism | Alzheimer Disease - drug therapy | Biomarkers | tau Proteins - metabolism | Amyloid Precursor Protein Secretases - antagonists & inhibitors | Alzheimer Disease - genetics
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 02/2017, Volume 102, Issue 2, pp. 525 - 534
CONTEXT:Stress fractures are repetitive use injuries in which recurrent strains lead to material fatigue and microarchitectural discontinuities. They account...
VITAMIN-D | WOMEN | DIAGNOSIS | LOWER-EXTREMITY | RISK-FACTORS | BONE-MINERAL DENSITY | FEMALE ATHLETE TRIAD | ORAL-CONTRACEPTIVE PILL | ENDOCRINOLOGY & METABOLISM | TERIPARATIDE | EXERCISE | Fractures, Stress - epidemiology | Humans | Fractures, Stress - metabolism | Calcium | Bisphosphonates | Osteoporosis | Densitometers | Body mass index | Biomedical materials | Vitamin D | Biocompatibility | Differential diagnosis | Supplementation | Densitometry | Injuries | Stresses | Energy intake | Calcium (dietary) | Phenotypes | Menstruation | Dietary supplements | Case reports | Fatigue | Dietary intake | Bone healing | Athletes | Stress | Bone mass | Fractures | Diet | Body mass | Parathyroid hormone | Body size | Disturbances | Bone mineral density
VITAMIN-D | WOMEN | DIAGNOSIS | LOWER-EXTREMITY | RISK-FACTORS | BONE-MINERAL DENSITY | FEMALE ATHLETE TRIAD | ORAL-CONTRACEPTIVE PILL | ENDOCRINOLOGY & METABOLISM | TERIPARATIDE | EXERCISE | Fractures, Stress - epidemiology | Humans | Fractures, Stress - metabolism | Calcium | Bisphosphonates | Osteoporosis | Densitometers | Body mass index | Biomedical materials | Vitamin D | Biocompatibility | Differential diagnosis | Supplementation | Densitometry | Injuries | Stresses | Energy intake | Calcium (dietary) | Phenotypes | Menstruation | Dietary supplements | Case reports | Fatigue | Dietary intake | Bone healing | Athletes | Stress | Bone mass | Fractures | Diet | Body mass | Parathyroid hormone | Body size | Disturbances | Bone mineral density
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 10/2017, Volume 15, Issue 10, pp. 1889 - 1900
Summary Thrombotic thrombocytopenic purpura (TTP), a potentially fatal clinical syndrome, is primarily caused by autoantibodies against the von Willebrand...
diagnosis | therapeutics | pathology | thrombotic microangiopathies | von Willebrand factor | HEMOLYTIC-UREMIC-SYNDROME | VON-WILLEBRAND-FACTOR | FACTOR-CLEAVING PROTEASE | MEDIATED GENE-THERAPY | PLASMA-EXCHANGE THERAPY | ADAMTS13 ACTIVITY | DISSEMINATED INTRAVASCULAR COAGULATION | ADVERSE-REACTIONS SONAR | RENAL-FAILURE | PERIPHERAL VASCULAR DISEASE | MALIGNANT HYPERTENSION | HEMATOLOGY | Recombinant Proteins - therapeutic use | Genetic Therapy | Predictive Value of Tests | Autoantibodies - blood | Humans | Plasma Exchange | ADAMTS13 Protein - blood | ADAMTS13 Protein - immunology | Hemostasis | Immunotherapy | Thrombocytopenia - therapy | Diagnosis, Differential | ADAMTS13 Protein - therapeutic use | Risk Factors | Treatment Outcome | Purpura, Thrombotic Thrombocytopenic - diagnosis | Purpura, Thrombotic Thrombocytopenic - epidemiology | Thrombocytopenia - blood | ADAMTS13 Protein - genetics | Anemia, Hemolytic - therapy | Anemia, Hemolytic - diagnosis | Thrombocytopenia - diagnosis | Purpura, Thrombotic Thrombocytopenic - therapy | Anemia, Hemolytic - blood | Purpura, Thrombotic Thrombocytopenic - blood | Autoimmunity | Autoantibodies | Anemia | Development and progression | Homeopathy | Materia medica and therapeutics | Thrombocytopenic purpura | Haptoglobin | Therapeutics | Von Willebrand factor | Hemoglobin | Diagnosis | Health aspects | Corticoids | Plasma | Cyclosporins | Pathogenesis | Prophylaxis | Antagonists | Splenectomy | Hemolytic anemia | Remission | Metalloproteinase | Thrombocytopenia | Thrombotic microangiopathy | Hemolytic uremic syndrome | Immunomodulation | Rituximab | Morbidity | L-Lactate dehydrogenase | Cyclophosphamide | Purpura | Lactic acid | Gene therapy | Platelets | Pathology | Thrombotic Microangiopathies | von Willebrand Factor
diagnosis | therapeutics | pathology | thrombotic microangiopathies | von Willebrand factor | HEMOLYTIC-UREMIC-SYNDROME | VON-WILLEBRAND-FACTOR | FACTOR-CLEAVING PROTEASE | MEDIATED GENE-THERAPY | PLASMA-EXCHANGE THERAPY | ADAMTS13 ACTIVITY | DISSEMINATED INTRAVASCULAR COAGULATION | ADVERSE-REACTIONS SONAR | RENAL-FAILURE | PERIPHERAL VASCULAR DISEASE | MALIGNANT HYPERTENSION | HEMATOLOGY | Recombinant Proteins - therapeutic use | Genetic Therapy | Predictive Value of Tests | Autoantibodies - blood | Humans | Plasma Exchange | ADAMTS13 Protein - blood | ADAMTS13 Protein - immunology | Hemostasis | Immunotherapy | Thrombocytopenia - therapy | Diagnosis, Differential | ADAMTS13 Protein - therapeutic use | Risk Factors | Treatment Outcome | Purpura, Thrombotic Thrombocytopenic - diagnosis | Purpura, Thrombotic Thrombocytopenic - epidemiology | Thrombocytopenia - blood | ADAMTS13 Protein - genetics | Anemia, Hemolytic - therapy | Anemia, Hemolytic - diagnosis | Thrombocytopenia - diagnosis | Purpura, Thrombotic Thrombocytopenic - therapy | Anemia, Hemolytic - blood | Purpura, Thrombotic Thrombocytopenic - blood | Autoimmunity | Autoantibodies | Anemia | Development and progression | Homeopathy | Materia medica and therapeutics | Thrombocytopenic purpura | Haptoglobin | Therapeutics | Von Willebrand factor | Hemoglobin | Diagnosis | Health aspects | Corticoids | Plasma | Cyclosporins | Pathogenesis | Prophylaxis | Antagonists | Splenectomy | Hemolytic anemia | Remission | Metalloproteinase | Thrombocytopenia | Thrombotic microangiopathy | Hemolytic uremic syndrome | Immunomodulation | Rituximab | Morbidity | L-Lactate dehydrogenase | Cyclophosphamide | Purpura | Lactic acid | Gene therapy | Platelets | Pathology | Thrombotic Microangiopathies | von Willebrand Factor
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2011, Volume 29, Issue 14, pp. 1924 - 1933
The systemic amyloidoses are a group of complex diseases caused by tissue deposition of misfolded proteins that results in progressive organ damage. The most...
INTRAVENOUS MELPHALAN | PHASE-II TRIAL | ORAL MELPHALAN | BRAIN NATRIURETIC PEPTIDE | LIGHT-CHAIN AMYLOIDOSIS | ONCOLOGY | PRIMARY SYSTEMIC AMYLOIDOSIS | AL PRIMARY AMYLOIDOSIS | HIGH-DOSE MELPHALAN | SERUM CARDIAC TROPONINS | STEM-CELL TRANSPLANTATION | Diagnosis, Differential | Prognosis | Amyloidosis - genetics | Humans | Amyloidosis - diagnosis | Amyloidosis - drug therapy | Amyloidosis - etiology | Immunoglobulin Light Chains - metabolism | Index Medicus | Jcoed | Review
INTRAVENOUS MELPHALAN | PHASE-II TRIAL | ORAL MELPHALAN | BRAIN NATRIURETIC PEPTIDE | LIGHT-CHAIN AMYLOIDOSIS | ONCOLOGY | PRIMARY SYSTEMIC AMYLOIDOSIS | AL PRIMARY AMYLOIDOSIS | HIGH-DOSE MELPHALAN | SERUM CARDIAC TROPONINS | STEM-CELL TRANSPLANTATION | Diagnosis, Differential | Prognosis | Amyloidosis - genetics | Humans | Amyloidosis - diagnosis | Amyloidosis - drug therapy | Amyloidosis - etiology | Immunoglobulin Light Chains - metabolism | Index Medicus | Jcoed | Review
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 08/2015, Volume 492, Issue 1-2, pp. 73 - 79
Deep eutectic solvents (DES) can be formed by bioactive compounds or pharmaceutical ingredients. A therapeutic DES (THEDES) based on ibuprofen, a non-steroidal...
Therapeutic deep eutectic solvents | Drug delivery systems | Supercritical carbon dioxide | Biodegradable polymers | Ibuprofen | DRUG | POLYMERS | DELIVERY SYSTEMS | COMPOSITES | SUBCRITICAL CO2 | TISSUE ENGINEERING APPLICATIONS | PHARMACOLOGY & PHARMACY | REGENERATIVE MEDICINE | SCAFFOLDS | IONIC LIQUIDS | Microscopy, Electron, Scanning | Solvents - chemistry | Solubility | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Delayed-Action Preparations - chemistry | Menthol - chemistry | X-Ray Microtomography | Drug Delivery Systems | Polyesters - chemistry | Starch - chemistry | Technology, Pharmaceutical | Ibuprofen - chemistry | Drug Liberation | Calorimetry, Differential Scanning | Biological products | Biomimetics | Tissue engineering | Health aspects
Therapeutic deep eutectic solvents | Drug delivery systems | Supercritical carbon dioxide | Biodegradable polymers | Ibuprofen | DRUG | POLYMERS | DELIVERY SYSTEMS | COMPOSITES | SUBCRITICAL CO2 | TISSUE ENGINEERING APPLICATIONS | PHARMACOLOGY & PHARMACY | REGENERATIVE MEDICINE | SCAFFOLDS | IONIC LIQUIDS | Microscopy, Electron, Scanning | Solvents - chemistry | Solubility | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Delayed-Action Preparations - chemistry | Menthol - chemistry | X-Ray Microtomography | Drug Delivery Systems | Polyesters - chemistry | Starch - chemistry | Technology, Pharmaceutical | Ibuprofen - chemistry | Drug Liberation | Calorimetry, Differential Scanning | Biological products | Biomimetics | Tissue engineering | Health aspects
Journal Article
NATURE REVIEWS IMMUNOLOGY, ISSN 1474-1733, 08/2019, Volume 19, Issue 8, pp. 477 - 489
NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) is an intracellular sensor that detects a broad range of microbial motifs, endogenous danger signals...
AIM2 INFLAMMASOME | DIFFERENTIAL REQUIREMENT | K+ EFFLUX | IMMUNOLOGY | GASDERMIN-D | NF-KAPPA-B | INTERLEUKIN-1-BETA MATURATION | HUMAN MONOCYTES | CUTTING EDGE | NALP3 INFLAMMASOME | CELL-DEATH | Regulators | Cytokines | Caspase | Activation | Hazards | Inflammation | IL-1β | Caspase-1 | Interleukin 18 | Proteins | Microorganisms | Mitochondria | Pyrin protein | Cell death | Regulation | Metabolic pathways | Regulatory proteins
AIM2 INFLAMMASOME | DIFFERENTIAL REQUIREMENT | K+ EFFLUX | IMMUNOLOGY | GASDERMIN-D | NF-KAPPA-B | INTERLEUKIN-1-BETA MATURATION | HUMAN MONOCYTES | CUTTING EDGE | NALP3 INFLAMMASOME | CELL-DEATH | Regulators | Cytokines | Caspase | Activation | Hazards | Inflammation | IL-1β | Caspase-1 | Interleukin 18 | Proteins | Microorganisms | Mitochondria | Pyrin protein | Cell death | Regulation | Metabolic pathways | Regulatory proteins
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2007, Volume 8, Issue 7, pp. 642 - 650
Summary Gestational trophoblastic neoplasia comprises a unique group of human neoplastic diseases that derive from fetal trophoblastic tissues and represent...
Hematology, Oncology and Palliative Medicine | MAMMALIAN TARGET | SUPPRESSOR GENE P53 | DIFFERENTIAL-DIAGNOSIS | ACTIVATED PROTEIN-KINASE | ADHESION MOLECULE | ONCOLOGY | HYDATIDIFORM MOLE | RAPAMYCIN INHIBITORS | INTERMEDIATE TROPHOBLAST | ORAL MEK INHIBITOR | IN-NORMAL-PLACENTA | Pregnancy | Gestational Trophoblastic Disease - metabolism | Humans | Biomarkers, Tumor - metabolism | Female | Neoplasm Proteins - antagonists & inhibitors | Gestational Trophoblastic Disease - pathology | Biomarkers, Tumor - antagonists & inhibitors | Neoplasm Proteins - metabolism | Gestational Trophoblastic Disease - therapy
Hematology, Oncology and Palliative Medicine | MAMMALIAN TARGET | SUPPRESSOR GENE P53 | DIFFERENTIAL-DIAGNOSIS | ACTIVATED PROTEIN-KINASE | ADHESION MOLECULE | ONCOLOGY | HYDATIDIFORM MOLE | RAPAMYCIN INHIBITORS | INTERMEDIATE TROPHOBLAST | ORAL MEK INHIBITOR | IN-NORMAL-PLACENTA | Pregnancy | Gestational Trophoblastic Disease - metabolism | Humans | Biomarkers, Tumor - metabolism | Female | Neoplasm Proteins - antagonists & inhibitors | Gestational Trophoblastic Disease - pathology | Biomarkers, Tumor - antagonists & inhibitors | Neoplasm Proteins - metabolism | Gestational Trophoblastic Disease - therapy
Journal Article